Happening right now? Eye symptoms: go straight to an emergency department or eye doctor. Skin blanching, mottling or worsening pain: contact the clinic that injected you now, and go to the emergency department if you can't reach them within 10 minutes. Details under "What to do right now" below.
The Emergency That Should Never Happen but Must Be Prepared For
If you have experienced sudden skin blanching, severe pain, or color changes during or after a filler injection, you may have encountered — or narrowly avoided — vascular occlusion. This is the most serious complication in filler medicine, and understanding the mechanism is essential whether you are dealing with its aftermath or want to understand the risks before future treatment.
Understanding this process is not meant to create panic, but to serve a practical purpose: the earlier you recognize signs of occlusion, the better the chance of saving tissue.
Key Insight: Vascular occlusion rescue is a race against time, but not one with a fixed deadline. Eye symptoms are measured in minutes. For the skin, there is no safe period to wait, and starting late is still far better than not starting. This is why we emphasize prevention through ultrasound-guided injection, and why anyone with warning signs should act immediately rather than watch and wait.
Warning Signs to Recognize Immediately
If you have just received a filler injection or are within hours of treatment, the following five signs may indicate vascular occlusion (Vascular Occlusion) and require immediate medical attention — do not wait to see if symptoms resolve on their own:
- Disproportionate, intense pain that feels far worse than normal injection soreness — described by patients as "burning," "electric shock," or "deep aching"
- Sudden skin blanching — a white, pale patch appearing in or near the injection area, sometimes spreading outward in minutes
- Skin color changes — blanching followed by mottled blue, purple, or gray discoloration (Livedo Reticularis pattern is a key warning sign)
- Vision changes — blurred vision, double vision, partial or complete vision loss, eyelid drooping, or eye pain (any vision symptom after facial filler is a true emergency)
- Numbness, weakness, or facial drooping — these may indicate filler has reached arteries supplying nerves or even the brain
Not every occlusion hurts
Severe pain is a common sign, but not a required one. In a review of 365 cases of filler-related vision loss, pain was recorded in only 31.2%, and one reported patient had no blanching or other signs for the first 48 hours. A color change in the skin or any eye symptom counts as an emergency even if it doesn't hurt.
What to do right now
- Eye or nerve symptoms (blurred or lost vision, double vision, a drooping eyelid, an eye that won't move properly, facial weakness, slurred speech): go straight to an emergency department or an eye doctor. Contact the injector on the way, not instead, and don't wait for a call back.
- Skin symptoms (blanching, mottled purple or gray patches, pain that keeps getting worse): contact the clinic that injected you immediately. If you can't reach them within 10 minutes, go to an emergency department and say you suspect filler vascular occlusion.
- Bring this information: the filler brand and material, where it was injected, when, roughly how much, when symptoms started, and photos from your phone.
Treatment is decided and given by a doctor. Don't wait at home to see whether it settles, and don't try to treat it yourself with massage, heat, creams or medication.
Key Insight: The earlier treatment starts, the better the outcome usually is. People who wait "to see if it gets better" are the ones most likely to be left with scarring, so when in doubt, treat it as an emergency.
Pathophysiology of Vascular Occlusion
Two Occlusion Mechanisms
Direct intravascular embolism: The needle tip penetrates the arterial wall, and filler enters the arterial lumen under injection pressure, physically blocking blood flow downstream. This is a recognized mechanism of vascular compromise from soft-tissue fillers, documented in a clinical case series on filler-related vascular compromise (Beleznay et al., 2014).
Extravascular compression: Large filler volumes compress vessels externally. When external pressure exceeds intravascular pressure, blood flow is blocked.
← Swipe to see more →
| Comparison | Direct Arterial Embolism | Extravascular Compression |
|---|---|---|
| Mechanism | Filler enters vessel lumen | Filler compresses vessel externally |
| Onset speed | Usually immediate; occasionally hours to days later | Minutes to hours |
| Ischemia distribution | Along arterial territory | Local compression area |
| Severity | Usually more severe | Depends on compression degree |
| Treatment focus | Dissolve intravascular filler | Decompress (remove/disperse filler) |
| Blindness risk | Present (if ophthalmic artery affected) | Very low |
From Blanching to Scabbing: How the Skin Changes
The stages below follow the order described in the literature. The times are deliberately approximate: they vary with the area, how much was injected and when treatment starts, and treatment can stop the progression at any stage.
Stage 1: Blanching (immediately)
Blood flow is blocked and the tissue downstream loses its oxygen supply. The skin turns pale, capillary refill slows (pressed skin is slow to turn pink again), and there is often severe pain out of proportion to the procedure.
Stage 2: Mottling and dusky discoloration (minutes to hours)
A net-like purple pattern (livedo reticularis) appears, and the area turns dusky blue-red or blue-gray. The affected area may spread as the small vessels fail.
Stage 3: Blisters (a few days later)
Blisters or small pustules appear over the affected skin. In one report, a patient first seen on day 3 already had redness, pustules and livedo, and still healed without scarring after treatment.
Stage 4: Scab, separation and repair (days to weeks)
Damaged skin forms a dark scab (eschar) and separates from healthy tissue. Pain may actually lessen at this point because nerve endings in the area have been damaged, so less pain is not a sign of improvement. Wound care follows, and sometimes later reconstruction.
Can Vascular Occlusion Appear Hours or Days Later?
Yes, although it's less common. Most occlusions show immediately or within minutes. But the literature also describes cases where the first symptoms appeared several hours after injection, 28 hours later and two days later, and one patient had no signs at all for the first 48 hours. One proposed explanation is that filler already inside an artery moves further along over time until it blocks a smaller branch; compression from swelling is another.
So in the first few days after filler, treat any of these as possible occlusion and get seen immediately: pain that keeps getting worse, redness and swelling with a mottled pattern, or small blisters. To tell this apart from delayed inflammation, see swelling vs. a delayed inflammatory reaction.
Emergency Rescue Principles
Earlier Is Better, and Late Is Still Worth Treating
← Swipe to see more →
| When treatment starts | What tends to be happening | What it means |
|---|---|---|
| Immediately | Blanching, slow capillary refill, pain | The best chance of full recovery |
| Within hours | Mottling, dusky discoloration | Still to be treated as an emergency |
| Days later | Blisters, scabbing | Treatment can still limit the damage; one report healed without scarring after high-dose treatment began on day 3 (earlier low doses had failed) |
One author's high-dose hyaluronidase protocol reported no partial or complete skin loss when it was started within 2 days of onset. These are case reports and one author's experience, not a promise that every case will go this way, but they are why "it's been too long" is never a reason not to go.
What the Treating Doctor Does
These steps are decided and carried out by a doctor according to the situation; they are not things to try at home.
- Stop injecting immediately
- High-dose hyaluronidase (for HA fillers), repeated hourly until skin color, capillary refill and pain recover; this is the core of the high-dose protocol
- Supportive measures such as warmth, aspirin, low-molecular-weight heparin or hyperbaric oxygen, chosen case by case
- Ultrasound to locate the filler and guide treatment, increasingly used
- Close monitoring of how the affected area changes
Topical nitroglycerin paste is controversial: a consensus statement says so directly, an animal study found no improvement in blood flow, and a review advises using it only together with hyaluronidase, never instead of it.
Key Insight: Blindness is the most irreversible outcome. Once filler reaches the central retinal artery, even immediate treatment has very low probability of restoring vision. In an American Academy of Ophthalmology review, vision was unchanged in 137 of 196 cases with recorded outcomes (70%). Separately, a 365-case review found that having some vision left at the start predicts improvement, which is another reason to go immediately. Prevention — through ultrasound guidance, avoiding danger zones, slow small-volume injection — is the most important strategy. Learn about facial anatomy danger zones.
Clinical Implications for Revision Patients
For patients who have survived a vascular occlusion event, the aftermath often involves tissue damage that requires careful management — and an understanding of what caused the event in the first place. At FILLER REVISION, we see patients dealing with post-occlusion scarring, residual filler that contributed to the vascular compromise, and the anxiety of knowing filler remains near critical vessels. Ultrasound (Ultrasonography)-guided assessment can identify remaining filler deposits in relation to the vascular anatomy, helping determine whether residual material poses ongoing risk and whether removal is advisable. For patients considering future injectable treatments after a vascular event, this imaging-based understanding of their anatomy is essential for making safe decisions.
Special Area Risks
Everything in this section concerns the arterial route. Filler has a second, less-discussed path: entering a vein, it needs no retrograde travel and follows normal flow through the right heart into the pulmonary arteries, producing a non-thrombotic pulmonary embolism. The mechanism, the symptom window and why hyaluronidase cannot reach the lungs are covered in filler embolism's second route.
Nasal Occlusion
The nose is one of the most common sites for filler-related vascular occlusion. Patients with nose filler displacement may have experienced mild vascular compression events without realizing it.
Ophthalmic Artery Occlusion and Blindness
The most catastrophic outcome. Arteries around the eye connect with the ophthalmic artery system, so injection pressure can push filler backwards into the ophthalmic artery and on into the arteries of the retina.
The retina tolerates very little ischemia. Older textbook figures came from rhesus monkey experiments in which the retina showed no detectable damage after 97 minutes of occlusion and massive irreversible damage at around 240 minutes, and 90 to 240 minutes became the generally accepted range. Those figures should not be read as grace time. The animals were under barbiturate anaesthesia (itself neuroprotective) with uncontrolled body temperature, and the artery was clamped before its dural entry so collateral flow persisted. A 2018 re-examination of that evidence (BMC Ophthalmology, PMID 29669523) concludes that complete central retinal artery occlusion most likely causes infarction within 12 to 15 minutes. Incomplete occlusions may still benefit from treatment after longer intervals.
Eye symptoms are measured in minutes. A drooping eyelid, double vision, an eye that won't move properly, or blurred vision, even just one of these and even if you can still see, means going straight to an emergency department or an eye doctor without waiting for the injector to call back. In a review of 365 cases, a drooping eyelid (56.2%), eye movement problems (44.1%) and skin changes (73.2%) were common alongside vision loss, and having some vision left at the start was a significant predictor of improvement. Arriving early makes a difference.
What If the Filler Wasn't Hyaluronic Acid?
Hyaluronidase only breaks down hyaluronic acid. Other fillers can also block arteries and cause vision loss: published reports include at least 11 cases of visual impairment with calcium hydroxylapatite (CaHA), two with PLLA, two with PDLLA-CMC and one with PDLLA-HA. In products that combine HA with a collagen stimulator, only the HA part can be dissolved. For PCL fillers such as Ellansé, neither the microspheres nor the carrier gel is a substrate for hyaluronidase, and an expert consensus recommends high-volume saline flushing with mechanical dispersion first.
So when you go to the emergency department, tell them exactly which brand and material was injected; it changes what can be done. For lumps from these materials, see Juvelook and Lenisna nodules and what can be removed with Ellansé and Radiesse.
Real case → 36-hour delayed vascular rescue via ultrasound-guided IAHA — a case rescued with ultrasound-guided intra-arterial hyaluronidase after treatment outside the vessel had not worked.
The Importance of Prevention
Occlusion rescue is never as effective as prevention:
- Ultrasound-guided injection: Identify vessel locations in real time
- Understanding facial anatomy danger zones
- Small-volume, slow injection: Reduce injection pressure to lower retrograde embolization risk
- Aspiration test: Aspirate before injection to check needle tip is not intravascular (not 100% reliable)
- Cannula use: When appropriate, to reduce vessel puncture risk
- Emergency drugs ready: Enough hyaluronidase always on hand, as the core of emergency treatment
Learn about the filler repair evaluation process and our vascular occlusion treatment services. At FILLER REVISION, we believe the best vascular occlusion outcome is the one that never happens — and when it does, rapid recognition and evidence-based intervention save tissue and lives.
Frequently Asked Questions
How soon after a filler injection does vascular occlusion start — can it be delayed?
Most vascular occlusions show immediately or within minutes of injection, with sudden, disproportionate pain and skin blanching as the classic early signs. But it can be delayed: published cases describe first symptoms several hours later, 28 hours later and two days later, and one patient had no signs for the first 48 hours. In the first few days after filler, treat worsening pain, blanching, mottled or dusky discoloration, or small blisters as vascular compromise until proven otherwise, and get seen immediately rather than waiting for it to "declare itself."
How do I tell the difference between vascular occlusion and normal post-injection swelling?
Normal post-injection swelling is symmetric, mild, painless or only slightly tender, and appears within minutes evenly across the treated area. Vascular occlusion is asymmetric, intensely painful out of proportion to what was done, and involves color change — blanching, dusky purple, or grayish patches that follow a streaky pattern along an artery's course. The most reliable distinguishing feature is pain that worsens rather than settling, combined with any color change. If you are uncertain, take a photo for the record and then contact your injector or go to the emergency room straight away; don't wait an hour to compare.
I just noticed pale or dusky patches several hours after my injection — is it too late to do anything?
It is not too late. Earlier is better, but late treatment is still worth it. One author's high-dose hyaluronidase protocol reported no partial or complete skin loss when it was started within 2 days of onset, and a published case whose high-dose treatment began on day 3, after lower doses had failed, healed without scarring by day 90. These are case reports and one author's experience, not a promise for every case. Go to an emergency room or contact your injector immediately, and never assume "it's been too long, nothing will help." If skin damage has already begun, the emergency team can also coordinate with plastic surgery.
Is vascular occlusion always painful?
No. Severe pain is common, but in a review of 365 cases of filler-related vision loss, pain was recorded in only 31.2%, and one reported patient had no symptoms for the first 48 hours. Any skin color change or eye symptom after filler needs urgent attention, even without pain.
My filler wasn't hyaluronic acid. Does dissolving still work?
Hyaluronidase only breaks down hyaluronic acid. With mixed products that contain HA, only the HA part is dissolved; with CaHA, PLLA, PDLLA or PCL, other approaches are needed. Vision loss has been reported with CaHA, PLLA and PDLLA; for PCL there are no published cases of blindness so far, but one case of facial artery embolism. Tell the emergency team exactly which brand and material you had.
After surviving a vascular occlusion, can I ever safely have filler again?
Many patients do — but only with significantly increased safety precautions and ideally not in the same anatomical area. The decision depends on three factors: (1) how the occlusion happened (technique error, anatomical variation, or unavoidable bad luck), (2) what filler and area you are considering, and (3) whether the injector uses ultrasound (Ultrasonography) guidance. After a vascular event, ultrasound-guided injection is no longer optional — it is essential. At FILLER REVISION, we evaluate post-occlusion patients with ultrasound to map their actual vascular anatomy, identify residual filler that may still pose risk, and discuss whether future injectables can be done safely. For some patients, the safer answer is to switch to non-injectable alternatives entirely.
Key Insight: Vascular occlusion is a war against time, but the best battle is the one that never begins. "Seeing" vessels under ultrasound before injecting is far better than starting rescue after occlusion occurs. Prevention is always more effective than treatment.
References
- Beleznay K, Humphrey S, Carruthers JD, Carruthers A. Vascular compromise from soft tissue augmentation: experience with 12 cases and recommendations for optimal outcomes. J Clin Aesthet Dermatol. 2014;7(9):37-43. PMID: 25276276.
- DeLorenzi C. New High Dose Pulsed Hyaluronidase Protocol for Hyaluronic Acid Filler Vascular Adverse Events. Aesthet Surg J. 2017;37(7):814-825. PMID: 28333326. DOI: 10.1093/asj/sjw251
- DeLorenzi C. Complications of injectable fillers, part 2: vascular complications. Aesthet Surg J. 2014;34(4):584-600. PMID: 24692598. DOI: 10.1177/1090820X14525035
- Cohen JL, Biesman BS, Dayan SH, DeLorenzi C, Lambros VS, Nestor MS, et al. Treatment of Hyaluronic Acid Filler-Induced Impending Necrosis With Hyaluronidase: Consensus Recommendations. Aesthet Surg J. 2015;35(7):844-9. PMID: 25964629. DOI: 10.1093/asj/sjv018
- Souza Felix Bravo B, Klotz De Almeida Balassiano L, Roos Mariano Da Rocha C, Barbosa De Sousa Padilha C, Martinezt Torrado C, Teixeira Da Silva R, et al. Delayed-type Necrosis after Soft-tissue Augmentation with Hyaluronic Acid. J Clin Aesthet Dermatol. 2015;8(12):42-7. PMID: 26705447.
- Cassiano D, Miyuki Iida T, Lúcia Recio A, Yarak S. Delayed skin necrosis following hyaluronic acid filler injection: A case report. J Cosmet Dermatol. 2020;19(3):582-584. PMID: 31925876. DOI: 10.1111/jocd.13287
- Karimi-Galougahi M, Raad N, Nourian N. High-Dose Hyaluronidase for Late-Onset Vascular Complications Following Hyaluronic Acid Filler. Aesthetic Plast Surg. 2026;50(1):507-510. PMID: 40770498. DOI: 10.1007/s00266-025-05086-2
- Chauhan A, Singh S. Management of Delayed Skin Necrosis Following Hyaluronic Acid Filler Injection Using Pulsed Hyaluronidase. J Cutan Aesthet Surg. 2019;12(3):183-186. PMID: 31619891. DOI: 10.4103/JCAS.JCAS_129_18
- Tagaya M, Arai K, Kapoor KM. Late Intervention Yet Successful Outcome with High-dose Pulsed Hyaluronidase for Forehead Filler Vascular Complication. Plast Reconstr Surg Glob Open. 2025;13(9):e7087. PMID: 40936506. DOI: 10.1097/GOX.0000000000007087
- Hayreh SS, Zimmerman MB, Kimura A, Sanon A. Central retinal artery occlusion. Retinal survival time. Exp Eye Res. 2004;78(3):723-36. PMID: 15106952. DOI: 10.1016/s0014-4835(03)00214-8
- Tobalem S, Schutz JS, Chronopoulos A. Central retinal artery occlusion - rethinking retinal survival time. BMC Ophthalmol. 2018;18(1):101. PMID: 29669523. DOI: 10.1186/s12886-018-0768-4
- Doyon VC, Liu C, Fitzgerald R, Humphrey S, Jones D, Carruthers JDA, et al. Update on Blindness From Filler: Review of Prognostic Factors, Management Approaches, and a Century of Published Cases. Aesthet Surg J. 2024;44(10):1091-1104. PMID: 38630871. DOI: 10.1093/asj/sjae091
- Foster J, Aakalu VK, Freitag SK, McCulley TJ, Tao JP, Vagefi MR, et al. Vision-Threatening Complications of Soft Tissue Fillers: A Report by the American Academy of Ophthalmology. Ophthalmology. 2025;132(8):935-944. PMID: 40167411. DOI: 10.1016/j.ophtha.2025.01.020
- Thanasarnaksorn W, Cotofana S, Rudolph C, Kraisak P, Chanasumon N, Suwanchinda A. Severe vision loss caused by cosmetic filler augmentation: Case series with review of cause and therapy. J Cosmet Dermatol. 2018;17(5):712-718. PMID: 30006992. DOI: 10.1111/jocd.12705
- Young SM, Goh ASC, Jeyabal P, Ooi ASH. Visual Loss in Biostimulator Injectables: A Review of Incidence, Risk Factors, Etiology and Management Proposal. Aesthetic Plast Surg. 2026;50(5):1994-2005. PMID: 41263987. DOI: 10.1007/s00266-025-05418-2
- de Melo F, Lin SL, Vercesi F, Aribi G, Santaella-Sosa E, Demirgean F, et al. Staged Management of Vascular Occlusion With Ellansé (Polycaprolactone): A Modified Delphi Expert Consensus. Aesthet Surg J Open Forum. 2026;8:ojag167. PMID: 42819331. DOI: 10.1093/asjof/ojag167
- Hwang CJ, Morgan PV, Pimentel A, Sayre JW, Goldberg RA, Duckwiler G. Rethinking the Role of Nitroglycerin Ointment in Ischemic Vascular Filler Complications: An Animal Model With ICG Imaging. Ophthalmic Plast Reconstr Surg. 2016;32(2):118-22. PMID: 25794030. DOI: 10.1097/IOP.0000000000000446
- Carley SK, Kraus CN, Cohen JL. Nitroglycerin, or Not, When Treating Impending Filler Necrosis. Dermatol Surg. 2020;46(1):31-40. PMID: 31356437. DOI: 10.1097/DSS.0000000000002030
- Kamrani P, Cox SE, Beleznay K, Humphrey S. From Bruising to Blindness: A Practical Guide to Identifying and Managing Hyaluronic Acid Filler Complications. Dermatol Surg. 2026. PMID: 42853707. DOI: 10.1097/DSS.0000000000005380
